{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dextromethorphan
to a specific field?
Status:
Possibly Marketed Outside US
Source:
21 CFR 349
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 349
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dextromethorphan D6 is a weak uncompetitive antagonist of the NMDA receptor. Dextromethorphan is also acts at nicotinic receptors, sigma-1 rcptor and serotonin and norepinephrine transporters. The incorporation of deuterium serves to reduce dextromethorphan first-pass liver metabolism. AVP-786 is an oral formulation of a combination of deuterated (d6)-dextromethorphan and an ultra-low dose of quinidine. Avanir Pharmaceuticals launched a phase III development program of AVP-786 for the treatment of agitation in patients with Alzheimer's disease.
Status:
Investigational
Source:
NCT03534063: Not Applicable Interventional Completed Pain, Postoperative
(2018)
Source URL:
Class:
PROTEIN
